In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

A Best Book of 2021 by Bloomberg BusinessWeek, Time, and The Washington PostThe bestselling author of Leonardo da Vinci and Steve Jobs returns with a “compelling” (The Washington Post) account of how Nobel Prize winner Jennifer Doudna and her colleagues launched a revolution that will allow us to cure diseases, fend off viruses, and have healthier babies.When Jennifer Doudna was in sixth grade, she came home one day to find that her dad had left a paperback titled The Double Helix on her bed. She put it aside, thinking it was one of those detective tales she loved. When she read it on a rainy Saturday, she discovered she was right, in a way. As she sped through the pages, she became enthralled by the intense drama behind the competition to discover the code of life. Even though her high school counselor told her girls didn’t become scientists, she decided she would.Driven by a passion to understand how nature works and to turn discoveries into inventions, she would help to make what the book’s author, James Watson, told her was the most important biological advance since his codiscovery of the structure of DNA. She and her collaborators turned a curiosity of nature into an invention that will transform the human race: an easy-to-use tool that can edit DNA. Known as CRISPR, it opened a brave new world of medical miracles and moral questions.The development of CRISPR and the race to create vaccines for coronavirus will hasten our transition to the next great innovation revolution. The past half-century has been a digital age, based on the microchip, computer, and internet. Now we are entering a life-science revolution. Children who study digital coding will be joined by those who study genetic code.Should we use our new evolution-hacking powers to make us less susceptible to viruses? What a wonderful boon that would be! And what about preventing depression? Hmmm…Should we allow parents, if they can afford it, to enhance the height or muscles or IQ of their kids?After helping to discover CRISPR, Doudna became a leader in wrestling with these moral issues and, with her collaborator Emmanuelle Charpentier, won the Nobel Prize in 2020. Her story is an “enthralling detective story” (Oprah Daily) that involves the most profound wonders of nature, from the origins of life to the future of our species.

This second edition of Biotechnology Entrepreneurship: Leading, Managing, and Commercializing Innovative Technologies is an authoritative, easy-to-read guide covering biotechnology entrepreneurship and the process of commercializing innovative biotechnology products. This best practice resource is for professional training programs, individuals starting a biotech venture, and for managers and experienced practitioners leading biotech enterprises. It is a valuable resource for those working at any level in the biotech industry, and for professionals who support and provide essential resources and services to the biotech industry. This practical, “how-to book is written by seasoned veterans experienced in each of the operational functions essential for starting, managing, and leading a successful biotech company. Biotechnology Entrepreneurship explains the biotech business components and underlying strategies, interspersed with practical lessons from successful biotech entrepreneurs, educators, and experienced practitioners. These veteran contributors share their insights on how to be successful in this challenging but exciting industry. Subjects range from technology licensing and translating an idea into a viable business, forming your legal company entity, securing angel and venture capital, navigating product development, FDA regulatory approval, and biomanufacturing. This book is a user-friendly guide to decision-making and overall strategy written as a hands-on management tool for leaders and managers of these dynamic biotechnology ventures. If you are contemplating starting a biotech company, are a manager at any level, a seasoned veteran, or service provider in the biotech industry, this book is a “must read.

In 1989, The Charismatic Joshua Boger Left Merck, Then America's Most Admired Business, To Found A Drug Company That Would Challenge Industry Giants And Transform Health Care. Journalist Barry Werth Described The Company's Tumultuous Early Days During The Aids Crisis In The Billion-dollar Molecule, A Celebrated Classic Of Science And Business Journalism. Now He Returns To Tell The Story Of Vertex's Bold Endurance And Eventual Success. The Pharmaceutical Business Is America's Toughest And One Of Its Most Profitable. It's Riskier And More Rigorous At Just About Every Stage Than Any Other Business, From The Towering Biological Uncertainties Inherent In Its Mission To Treat Disease; To The 30-to-1 Failure Rate In Bringing Out A Successful Medicine; To The Multibillion-dollar Cost Of Ramping Up A Successful Product; To Operating In The World's Most Regulated Industry, Matched Only By Nuclear Power. Werth Captures The Full Scope Of Vertex's 25-year Drive To Deliver Breakthrough Medicines.--from Publisher Description. Machine Generated Contents Note: Pt. 1 Feeding The Beast -- Pt. 2 Game Worth The Candle -- Pt. 3 Showtime. Barry Werth. Includes Bibliographical References And Index.

Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of biotech's problems; he offers the most sophisticated analysis yet on how the industry works. And he provides clear prescriptions for companies, investors, and policy makers seeking ways to improve the industry's performance. According to Pisano, the biotech industry's problems stem from its special character as a science-based business. This character poses three unique business challenges: how to finance highly risky investments under profound uncertainty and long time horizons for R&D, how to learn rapidly enough to keep pace with advances in drug science knowledge, and how to integrate capabilities across a broad spectrum of scientific and technological knowledge bases.The key to fixing the industry? Business models, organisational structures, and financing arrangements that place greater emphasis on integration and long-term learning over shorter—term 'monetisation' of intellectual property. Pisano maintains that all industry players—biotech firms, investors, universities, pharmaceutical companies, government regulators—can play a role in righting the industry. The payoff? Valuable improvements in health care, and a shinier future for human well-being.

EXPANDED THIRD EDITION includes Charlie's 2007 USC Law School Commencement address. Edited by Peter D. Kaufman. Brand New.

NATIONAL BOOK CRITICS CIRCLE AWARD WINNER •NATIONAL BESTSELLER • Geobiologist Hope Jahren has spent her life studying trees, flowers, seeds, and soil. Lab Girl is her revelatory treatise on plant life—but it is also a celebration of the lifelong curiosity, humility, and passion that drive every scientist."Does for botany what Oliver Sacks’s essays did for neurology, what Stephen Jay Gould’s writings did for paleontology.” —The New York TimesIn these pages, Hope takes us back to her Minnesota childhood, where she spent hours in unfettered play in her father’s college laboratory. She tells us how she found a sanctuary in science, learning to perform lab work “with both the heart and the hands.” She introduces us to Bill, her brilliant, eccentric lab manager. And she extends the mantle of scientist to each one of her readers, inviting us to join her in observing and protecting our environment.Warm, luminous, compulsively readable, Lab Girl vividly demonstrates the mountains that we can move when love and work come together.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how the core team--denied their share of the profits--went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time. In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks--and make the people who find that rare molecule astonishingly rich. For Blood and Money follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they're onto something big. What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. Vardi's narrative immerses readers in the recent explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, For Blood and Money illustrates why it's so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine.

"Autonomous is to biotech and AI what Neuromancer was to the Internet."―Neal Stephenson\n"Something genuinely and thrillingly new in the naturalistic, subjective, paradoxically humanistic but non-anthropomorphic depiction of bot-POV―and all in the service of vivid, solid storytelling."―William Gibson\nWhen anything can be owned, how can we be free\nEarth, 2144. Jack is an anti-patent scientist turned drug pirate, traversing the world in a submarine as a pharmaceutical Robin Hood, fabricating cheap scrips for poor people who can’t otherwise afford them. But her latest drug hack has left a trail of lethal overdoses as people become addicted to their work, doing repetitive tasks until they become unsafe or insane.\nHot on her trail, an unlikely pair: Eliasz, a brooding military agent, and his robotic partner, Paladin. As they race to stop information about the sinister origins of Jack’s drug from getting out, they begin to form an uncommonly close bond that neither of them fully understand.\nAnd underlying it all is one fundamental question: Is freedom possible in a culture where everything, even people, can be owned?

Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.In Science Lessons, Gordon Binder—CEO and chairman during 1988-2000—describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges—such as managing creative employees, navigating the IPO process, and protecting intellectual property.This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great—offering valuable lessons for all companies.

NEW YORK TIMES BESTSELLER • How will Artificial Intelligence affect crime, war, justice, jobs, society and our very sense of being human? The rise of AI has the potential to transform our future more than any other technology—and there’s nobody better qualified or situated to explore that future than Max Tegmark, an MIT professor who’s helped mainstream research on how to keep AI beneficial.How can we grow our prosperity through automation without leaving people lacking income or purpose? What career advice should we give today’s kids? How can we make future AI systems more robust, so that they do what we want without crashing, malfunctioning or getting hacked? Should we fear an arms race in lethal autonomous weapons? Will machines eventually outsmart us at all tasks, replacing humans on the job market and perhaps altogether? Will AI help life flourish like never before or give us more power than we can handle?What sort of future do you want? This book empowers you to join what may be the most important conversation of our time. It doesn’t shy away from the full range of viewpoints or from the most controversial issues—from superintelligence to meaning, consciousness and the ultimate physical limits on life in the cosmos.

#1 NEW YORK TIMES BESTSELLER • “Brilliant . . . a celebration of human ingenuity [and] the purest example of real-science sci-fi for many years . . . utterly compelling.”—The Wall Street JournalThe inspiration for the major motion pictureSix days ago, astronaut Mark Watney became one of the first people to walk on Mars.Now, he’s sure he’ll be the first person to die there.After a dust storm nearly kills him and forces his crew to evacuate while thinking him dead, Mark finds himself stranded and completely alone with no way to even signal Earth that he’s alive—and even if he could get word out, his supplies would be gone long before a rescue could arrive.Chances are, though, he won’t have time to starve to death. The damaged machinery, unforgiving environment, or plain-old “human error” are much more likely to kill him first.But Mark isn’t ready to give up yet. Drawing on his ingenuity, his engineering skills—and a relentless, dogged refusal to quit—he steadfastly confronts one seemingly insurmountable obstacle after the next. Will his resourcefulness be enough to overcome the impossible odds against him?NAMED ONE OF PASTE’S BEST NOVELS OF THE DECADE“A hugely entertaining novel [that] reads like a rocket ship afire . . . Weir has fashioned in Mark Watney one of the most appealing, funny, and resourceful characters in recent fiction.”—Chicago Tribune“As gripping as they come . . . You’ll be rooting for Watney the whole way, groaning at every setback and laughing at his pitchblack humor. Utterly nail-biting and memorable.”—Financial Times

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.

In 1921, forty-year-old schoolteacher Hans Duncker set off through the streets of Bremen. Near the cathedral, he heard a nightingale singing - but this was August and no one had ever heard a nightingale sing in the middle of the town at this time of year. In fact, the bird he heard was extraordinary - it was a special canary (a nightingale-canary) that Karl Reichs, a bird keeper, had engineered through a decade of dedicated breeding. With Reich's knowledge of birds and Duncker's expertise in genetics, the two joined forces and devised the audacious plan to create a brand new bird - a red canary. Favoured originally for their voices, canaries were once so rare that they were worth more than their weight in gold and had been exported in their millions. With Duncker and Reich's research, the canary once more took centre stage - this time in the race to create a genetically engineered animal. But it wasn't until an Englishman and an American recognised that the red canary would need to be a product of both nature AND nurture that the project was finally brought to fruition.

The latest groundbreaking tome from Tim Ferriss, the #1 New York Times best-selling author of The 4-Hour Workweek.From the author:“For the last two years, I’ve interviewed more than 200 world-class performers for my podcast, The Tim Ferriss Show. The guests range from super celebs (Jamie Foxx, Arnold Schwarzenegger, etc.) and athletes (icons of powerlifting, gymnastics, surfing, etc.) to legendary Special Operations commanders and black-market biochemists. For most of my guests, it’s the first time they’ve agreed to a two-to-three-hour interview. This unusual depth has helped make The Tim Ferriss Show the first business/interview podcast to pass 100 million downloads.“This book contains the distilled tools, tactics, and ‘inside baseball’ you won’t find anywhere else. It also includes new tips from past guests, and life lessons from new ‘guests’ you haven’t met.“What makes the show different is a relentless focus on actionable details. This is reflected in the questions. For example: What do these people do in the first sixty minutes of each morning? What do their workout routines look like, and why? What books have they gifted most to other people? What are the biggest wastes of time for novices in their field? What supplements do they take on a daily basis?“I don’t view myself as an interviewer. I view myself as an experimenter. If I can’t test something and replicate results in the messy reality of everyday life, I’m not interested.“Everything within these pages has been vetted, explored, and applied to my own life in some fashion. I’ve used dozens of the tactics and philosophies in high-stakes negotiations, high-risk environments, or large business dealings. The lessons have made me millions of dollars and saved me years of wasted effort and frustration.“I created this book, my ultimate notebook of high-leverage tools, for myself. It’s changed my life, and I hope the same for you.”

This book shows, for the first time, how modern biotechnology grew out of this century's hopes for a new relationship between biology and engineering. Long before recombinant DNA, these promised a new kind of technology. By exploring the rich and surprisingly overlooked complex of prophesies, industrial and scientific development and government programs, the book sheds new light on the expectations now held for biotechnology. A world-wide view, covering developments, not just in America but also in Europe and Japan, uncovers surprising links. This makes possible a coherent story to supersede the historical notes which have been available until now. This first history of biotechnology provides a readable and challenging account that will appeal to anyone interested in the development of this key component of modern industry.

A NEW YORK TIMES BESTSELLER“Brilliant and enthralling.” —The Wall Street JournalA paradigm-shifting book from an acclaimed Harvard Medical School scientist and one of Time’s most influential people.It’s a seemingly undeniable truth that aging is inevitable. But what if everything we’ve been taught to believe about aging is wrong? What if we could choose our lifespan?In this groundbreaking book, Dr. David Sinclair, leading world authority on genetics and longevity, reveals a bold new theory for why we age. As he writes: “Aging is a disease, and that disease is treatable.”This eye-opening and provocative work takes us to the frontlines of research that is pushing the boundaries on our perceived scientific limitations, revealing incredible breakthroughs—many from Dr. David Sinclair’s own lab at Harvard—that demonstrate how we can slow down, or even reverse, aging. The key is activating newly discovered vitality genes, the descendants of an ancient genetic survival circuit that is both the cause of aging and the key to reversing it. Recent experiments in genetic reprogramming suggest that in the near future we may not just be able to feel younger, but actually become younger.Through a page-turning narrative, Dr. Sinclair invites you into the process of scientific discovery and reveals the emerging technologies and simple lifestyle changes—such as intermittent fasting, cold exposure, exercising with the right intensity, and eating less meat—that have been shown to help us live younger and healthier for longer. At once a roadmap for taking charge of our own health destiny and a bold new vision for the future of humankind, Lifespan will forever change the way we think about why we age and what we can do about it.

A groundbreaking book about how ancient DNA has profoundly changed our understanding of human history.Geneticists like David Reich have made astounding advances in the field of genomics, which is proving to be as important as archeology, linguistics, and written records as a means to understand our ancestry.In Who We Are and How We Got Here, Reich allows readers to discover how the human genome provides not only all the information a human embryo needs to develop but also the hidden story of our species. Reich delves into how the genomic revolution is transforming our understanding of modern humans and how DNA studies reveal deep inequalities among different populations, between the sexes, and among individuals. Provocatively, Reich’s book suggests that there might very well be biological differences among human populations but that these differences are unlikely to conform to common stereotypes.Drawing upon revolutionary findings and unparalleled scientific studies, Who We Are and How We Got Here is a captivating glimpse into humankind—where we came from and what that says about our lives today.

About the Author\\nReinhard Renneberg received his PhD at Central Institute of Molecular Biology, Berlin, German Democratic Republic in 1979. Since 1995 Professor Renneberg has been heading the Biosensor group at the Department of Chemistry of the Hong Kong University of Science and Technology. He is an expert in biotests, biosensors and signal amplification technologies. Dr. Renneberg is also the inventor of Cardiodetect, a rapid fatty acid-binding protein (FABP) immunotest which allows diagnosis or exclusion of acute myocardial infarction within half an hour after the onset of symptom and of InfectCheck, a barcode-style lateral flow assay for semi-quantitative detection of C-reactive protein (CRP) in distinguishing between bacterial and viral infections.\nDr. Renneberg is the author of several books on biotechnology, including the award-winning textbook Biotechnology for Beginners which the university includes in many of its training packages. He advises a wide range of biotechnology companies as expert content provider, pedagogical expert and top-level academic relay for biotechnology education.\\nBiotechnology for Beginners, Third Edition presents the latest developments in the evolving field of biotechnology which has grown to such an extent over the past few years that increasing numbers of professional’s work in areas that are directly impacted by the science. This book offers an exciting and colorful overview of biotechnology for professionals and students in a wide array of the life sciences, including genetics, immunology, biochemistry, agronomy and animal science. This book will also appeals to lay readers who do not have a scientific background but are interested in an entertaining and informative introduction to the key aspects of biotechnology.\nAuthors Renneberg and Loroch discuss the opportunities and risks of individual technologies and provide historical data in easy-to-reference boxes, highlighting key topics. The book covers all major aspects of the field, from food biotechnology to enzymes, genetic engineering, viruses, antibodies, and vaccines, to environmental biotechnology, transgenic animals, analytical biotechnology, and the human genome.

Imagine a future in which human beings have become immune to all viruses, in which bacteria can custom-produce everyday items, like a drinking cup, or generate enough electricity to end oil dependency. Building a house would entail no more work than planting a seed in the ground. These scenarios may seem far-fetched, but pioneering geneticist George Church and science writer Ed Regis show that synthetic biology is bringing us ever closer to making such visions a reality. In Regenesis, Church and Regis explore the possibilities—and perils—of the emerging field of synthetic biology. Synthetic biology, in which living organisms are selectively altered by modifying substantial portions of their genomes, allows for the creation of entirely new species of organisms. Until now, nature has been the exclusive arbiter of life, death, and evolution; with synthetic biology, we now have the potential to write our own biological future. Indeed, as Church and Regis show, it even enables us to revisit crucial points in the evolution of life and, through synthetic biological techniques, choose different paths from those nature originally took. Such exploits will involve far more than just microbial tinkering. Full-blown genomic engineering will make possible incredible feats, from resurrecting woolly mammoths and other extinct organisms to creating mirror life forms with a molecular structure the opposite of our own. These technologies—far from the out-of-control nightmare depicted in science fiction—have the power to improve human and animal health, increase our intelligence, enhance our memory, and even extend our life span. A breathtaking look at the potential of this world-changing technology, Regenesis is nothing less than a guide to the future of life.

Revolutionary advances in biotechnology research and innovation have benefitted millions of patients in the world. The cycle of discovering, developing and delivering novel medications to combat severe disease conditions is an ongoing process. This user-friendly guide to starting a biotech company covers the background science, drug development, and key steps to a successful biotech startup The future will surely unfold the fruits of biotechnology research in its quest to unveil newer remedies for combating the threat of disease in the world.

We normally think of viruses in terms of the devastating diseases they cause, from smallpox to AIDS. But in The Life of a Virus, Angela N. H. Creager introduces us to a plant virus that has taught us much of what we know about all viruses, including the lethal ones, and that also played a crucial role in the development of molecular biology. Focusing on the tobacco mosaic virus (TMV) research conducted in Nobel laureate Wendell Stanley's lab, Creager argues that TMV served as a model system for virology and molecular biology, much as the fruit fly and laboratory mouse have for genetics and cancer research. She examines how the experimental techniques and instruments Stanley and his colleagues developed for studying TMV were generalized not just to other labs working on TMV, but also to research on other diseases such as poliomyelitis and influenza and to studies of genes and cell organelles. The great success of research on TMV also helped justify increased spending on biomedical research in the postwar years (partly through the National Foundation for Infantile Paralysis's March of Dimes)—a funding priority that has continued to this day.

Richard Dawkins' brilliant reformulation of the theory of natural selection has the rare distinction of having provoked as much excitement and interest outside the scientific community as within it. His theories have helped change the whole nature of the study of social biology, and have forced thousands of readers to rethink their beliefs about life.In his internationally bestselling, now classic volume, The Selfish Gene, Dawkins explains how the selfish gene can also be a subtle gene. The world of the selfish gene revolves around savage competition, ruthless exploitation, and deceit, and yet, Dawkins argues, acts of apparent altruism do exist in nature. Bees, for example, will commit suicide when they sting to protect the hive, and birds will risk their lives to warn the flock of an approaching hawk.This 30th anniversary edition of Dawkins' fascinating book retains all original material, including the two enlightening chapters added in the second edition. In a new Introduction the author presents his thoughts thirty years after the publication of his first and most famous book, while the inclusion of the two-page original Foreword by brilliant American scientist Robert Trivers shows the enthusiastic reaction of the scientific community at that time. This edition is a celebration of a remarkable exposition of evolutionary thought, a work that has been widely hailed for its stylistic brilliance and deep scientific insights, and that continues to stimulate whole new areas of research today.

A bold, inspiring, and multi-disciplinary exploration of cutting-edge human knowledge and capabilities--and how to harness their awesome, but terrifying potential In Superconvergence, leading futurist and OneShared.World founder Jamie Metzl explores how genome sequencing, gene editing, artificial intelligence, and other technologies are not only changing our lives, but catalyzing each other in radical and accelerating ways. These technologies have the potential to improve our health, feed billions of people, supercharge our economies, and store essential information for millions of years, but can also--if we are not careful--do immeasurable harm. The challenge we face is that while the ability to engineer the world around us is advancing exponentially, our processes for understanding the scope, scale, and implications of these changes is only increasing linearly and our capacity to govern our godlike capabilities wisely is only inching forward glacially. Luckily, in Jamie Metzl we have a thinker who has followed this phenomenon for decades and who integrates science, history, politics, and international affairs to envision a future that many specialists, almost by definition, cannot see. In Superconvergence, Metzl gives us the definitive account of the technological precipice on which we stand and the map to where we go from here.

Every year the average number of prescriptions purchased by Americans increases, as do healthcare expenditures, which are projected to reach one-fifth of the U.S. gross domestic product by 2020. In Drugs for Life, Joseph Dumit considers how our burgeoning consumption of medicine and cost of healthcare not only came to be, but also came to be taken for granted. For several years, Dumit attended pharmaceutical industry conferences; spoke with marketers, researchers, doctors, and patients; and surveyed the industry's literature regarding strategies to expand markets for prescription drugs. He concluded that underlying the continual growth in medications, disease categories, costs, and insecurity is a relatively new perception of ourselves as inherently ill and in need of chronic treatment. This perception is based on clinical trials that we have largely outsourced to pharmaceutical companies. Those companies in turn see clinical trials as investments and measure the value of those investments by the size of the market and profits that they will create. They only ask questions for which the answer is more medicine. Drugs for Life challenges our understanding of health, risks, facts, and clinical trials, the very concepts used by pharmaceutical companies to grow markets to the point where almost no one can imagine a life without prescription drugs.

This Book Is Intended To Expose Students Of Life Sciences To Biotechnology, A Vibrant And Ever-Evolving Discipline. You Will Gain Knowledge Of Methodologies And Tools Used In This Field. Read, Enjoy And Learn As This Book Walk You Through The Fundamentals Of Biotechnology And Equips You With Many Of The Necessary Skills To Excel In This Field.\\nIn This Book, You Will: What Is Biotechnology? Biotechnology Law Patent Law- General Biotech Invention- Meaning & Overview Invention Or Discovery? Factors That May Indicate Invention Does Biotechnology Invention Need Patent Protection?\\nThe Book Gives General Ideas About Biotechnology, Describes Its Main Objects, Outlines The Basics Of Cellular, Tissue And Genetic Engineering, Cryopreservation. The Part Includes The Basics Of Industrial Biotechnology, Enzymatic Engineering, Environmental Biotechnology, Nanobiotechnology The Book will be extremely useful for all students studying Biotechnology at Graduate or Post Graduate level.

The definitive biotechnology industry primer, now in its 3rd edition. Building Biotechnology provides a comprehensive fundamentals-based overview of the commercialization of biotechnology. Expanding on this foundation to ensure a practical appreciation of operational issues in the biotechnology industry, Building Biotechnology adds real-world examples on topics such as the hidden pitfalls of common operational decisions; practical considerations in selecting business models and funding options; strategies to overcome developmental failures; and, methods to leverage options to strengthen development plans.

Build real-world artificial intelligence apps on AWS to overcome challenges faced by healthcare providers and payers, as well as pharmaceutical, life sciences research, and commercial organizations Key Features Learn about healthcare industry challenges and how machine learning can solve them Explore AWS machine learning services and their applications in healthcare and life sciences Discover practical coding instructions to implement machine learning for healthcare and life sciences Book Description\nWhile machine learning is not new, it's only now that we are beginning to uncover its true potential in the healthcare and life sciences industry. The availability of real-world datasets and access to better compute resources have helped researchers invent applications that utilize known AI techniques in every segment of this industry, such as providers, payers, drug discovery, and genomics.\nThis book starts by summarizing the introductory concepts of machine learning and AWS machine learning services. You'll then go through chapters dedicated to each segment of the healthcare and life sciences industry. Each of these chapters has three key purposes -- First, to introduce each segment of the industry, its challenges, and the applications of machine learning relevant to that segment. Second, to help you get to grips with the features of the services available in the AWS machine learning stack like Amazon SageMaker and Amazon Comprehend Medical. Third, to enable you to apply your new skills to create an ML-driven solution to solve problems particular to that segment. The concluding chapters outline future industry trends and applications.\nBy the end of this book, you'll be aware of key challenges faced in applying AI to healthcare and life sciences industry and learn how to address those challenges with confidence. What you will learn Explore the healthcare and life sciences industry Find out about the key applications of AI in different industry segments Apply AI to medical images, clinical notes, and patient data Discover security, privacy, fairness, and explainability best practices Explore the AWS ML stack and key AI services for the industry Develop practical ML skills using code and AWS services Discover all about industry regulatory requirements Who this book is for\nThis book is specifically tailored toward technology decision-makers, data scientists, machine learning engineers, and anyone who works in the data engineering role in healthcare and life sciences organizations. Whether you want to apply machine learning to overcome common challenges in the healthcare and life science industry or are looking to understand the broader industry AI trends and landscape, this book is for you. This book is filled with hands-on examples for you to try as you learn about new AWS AI concepts. Table of Contents Introducing Machine Learning and the AWS Machine Learning Stack Exploring Key AWS Machine Learning Services for Healthcare and Life Sciences Machine Learning for Patient Risk Stratification Using Machine Learning to Improve Operational Efficiency for Healthcare Providers Implementing Machine Learning for Healthcare Payors Implementing Machine Learning for Medical Devices and Radiology Images Applying Machine Learning to Genomics Applying Machine Learning to Molecular Data Applying Machine Learning to Clinical Trials and Pharmacovigilance Utilizing Machine Learning in the Pharmaceutical Supply Chain Understanding Common Industry Challenges and Solutions Understanding Current Industry Trends and Future Applications

In this classic book, the distinguished science writer Horace Freeland Judson tells the story of the birth and early development of molecular biology in the US, the UK, and France. The fascinating story of the golden period from the revelation of the double helix of DNA to the cracking of the genetic code and first glimpses of gene regulation is told largely in the words of the main players, all of whom Judson interviewed extensively. The result is a book widely regarded as the best history of recent biological science yet published.This commemorative edition, honoring the memory of the author who died in 2011, contains essays by his daughter Olivia Judson, Matthew Meselson, and Mark Ptashne and an obituary by Jason Pontin. It contains all the content added to previous editions, including essays on some of the principal historical figures involved, such as Rosalind Franklin, and a sketch of the further development of molecular biology in the era of recombinant DNA.

This is a detailed history of one of the most important and dramatic episodes in modern science, recounted from the novel vantage point of the dawn of the information age and its impact on representations of nature, heredity, and society. Drawing on archives, published sources, and interviews, the author situates work on the genetic code (1953-70) within the history of life science, the rise of communication technosciences (cybernetics, information theory, and computers), the intersection of molecular biology with cryptanalysis and linguistics, and the social history of postwar Europe and the United States. Kay draws out the historical specificity in the process by which the central biological problem of DNA-based protein synthesis came to be metaphorically represented as an information code and a writing technology—and consequently as a “book of life.” Deploying analyses of language, cryptology, and information theory, the author persuasively argues that, technically speaking, the genetic code is not a code, DNA is not a language, and the genome is not an information system (objections voiced by experts as early as the 1950s). Thus her historical reconstruction and analyses also serve as a critique of the new genomic biopower. Genomic textuality has become a fact of life, a metaphor literalized, she claims, as human genome projects promise new levels of control over life through the meta-level of information: control of the word (the DNA sequences) and its editing and rewriting. But the author shows how the humbling limits of these scriptural metaphors also pose a challenge to the textual and material mastery of the genomic “book of life.”

The common fruit fly, Drosophila, has long been one of the most productive of all laboratory animals. From 1910 to 1940, the center of Drosophila culture in America was the school of Thomas Hunt Morgan and his students Alfred Sturtevant and Calvin Bridges. They first created "standard" flies through inbreeding and by organizing a network for exchanging stocks of flies that spread their practices around the world. In Lords of the Fly, Robert E. Kohler argues that fly laboratories are a special kind of ecological niche in which the wild fruit fly is transformed into an artificial animal with a distinctive natural history. He shows that the fly was essentially a laboratory tool whose startling productivity opened many new lines of genetic research. Kohler also explores the moral economy of the "Drosophilists": the rules for regulating access to research tools, allocating credit for achievements, and transferring authority from one generation of scientists to the next. By closely examining the Drosophilists' culture and customs, Kohler reveals essential features of how experimental scientists do their work.

In the late nineteenth and the early twentieth century, it was widely assumed that society ought to foster the breeding of those who possessed favorable traits and discourage the breeding of those who did not. Controlled human breeding, or "eugenics" as it was called, was a movement with broad support that lasted into the 1930s. In this concise historical account, the author answers the questions of why eugenics, the search for means to propagate only "good genes," was so attractive earlier in the twentieth century, why it then fell into disrepute, and whether it has returned today in the new guise of genetic counseling.

The biologist Jacques Loeb (1859-1924) helped to shape the practice of modern biological research through his radical emphasis on reductionist experimentation. This biography traces his career and convincingly argues that Loeb's desire to control organisms, manifested in studies of both reproduction and animal behavior, contributed to a new self-image for biologists. The author places Loeb's experiments and the controversies they generated in their intellectual and institutional contexts, tracing his influence on the development of behaviorism, genetics, and reproductive biology.

Making Mice blends scientific biography, institutional history, and cultural history to show how genetically standardized mice came to play a central role in contemporary American biomedical research.\n Karen Rader introduces us to mouse "fanciers" who bred mice for different characteristics, to scientific entrepreneurs like geneticist C. C. Little, and to the emerging structures of modern biomedical research centered around the National Institutes of Health. Throughout Making Mice, Rader explains how the story of mouse research illuminates our understanding of key issues in the history of science such as the role of model organisms in furthering scientific thought. Ultimately, genetically standardized mice became icons of standardization in biomedicine by successfully negotiating the tension between the natural and the man-made in experimental practice.\n This book will become a landmark work for its understanding of the cultural and institutional origins of modern biomedical research. It will appeal not only to historians of science but also to biologists and medical researchers.

Rich with the voices and stories of participants, these touching, firsthand accounts examine how women of diverse racial, ethnic, class and religious backgrounds perceive prenatal testing, the most prevalent and routinized of the new reproducing technologies. Based on the author's decade of research and her own personal experiences with amniocentesis, Testing Women, Testing the Fetus explores the "geneticization" of family life in all its complexity and diversity.

When we think about the Victorian age, we usually envision people together with animals: the Queen and her pugs, the sportsman with horses and hounds, the big game hunter with his wild kill, the gentleman farmer with a prize bull. Harriet Ritvo here gives us a vivid picture of how animals figured in English thinking during the nineteenth century and, by extension, how they served as metaphors for human psychological needs and sociopolitical aspirations.\nVictorian England was a period of burgeoning scientific cattle breeding and newly fashionable dog shows; an age of Empire and big game hunting; an era of reform and reformers that saw the birth of the Royal SPCA. Ritvo examines Victorian thinking about animals in the context of other lines of thought: evolution, class structure, popular science and natural history, imperial domination. The papers and publications of people and organizations concerned with agricultural breeding, veterinary medicine, the world of pets, vivisection and other humane causes, zoos, hunting at home and abroad, all reveal underlying assumptions and deeply held convictions―for example, about Britain’s imperial enterprise, social discipline, and the hierarchy of orders, in nature and in human society.\nThus this book contributes a new new topic of inquiry to Victorian studies; its combination of rhetorical analysis with more conventional methods of historical research offers a novel perspective on Victorian culture. And because nineteenth-century attitudes and practices were often the ancestors of contemporary ones, this perspective can also inform modern debates about human–animal interactions.

"A tour-de-force for anyone who is interested in the biotech industry. I applaud the enormous achievement of Cynthia Robbins-Roth."-Frederick Frank, Senior Managing Director & Vice Chair, Lehman Brothers"From Alchemy to IPO tells the dramatic story of this revolutionary industry as only an insider can."-George Rathmann, President and CEO, ICOS Corporation, Chairman Emeritus, AmgenWritten by a well-known industry insider, From Alchemy to IPO addresses the coming-of-age of biotech products and companies and traces the history of biotechnology from its early inception in the seventies to today's heyday of new solutions and breakthrough treatments. It describes the amazing entrepreneurial trail of product development, novel business models, and critical trials that eventually pave the way to market. This is the first book to accurately record the inner workings of an industry-biotechnology-that's on the verge of living up to its monumental promise to change the world as we know it.

What is life?Humans have been asking this question for thousands of years. But as technology has advanced and our understanding of biology has deepened, the answer has evolved. For decades, scientists have been exploring the limits of nature by modifying and manipulating DNA, cells and whole organisms to create new ones that could never have existed on their own.In Creation, science writer Adam Rutherford explains how we are now radically exceeding the boundaries of evolution and engineering entirely novel creatures—from goats that produce spider silk in their milk to bacteria that excrete diesel to genetic circuits that identify and destroy cancer cells. As strange as some of these creations may sound, this new, synthetic biology is helping scientists develop radical solutions to some of the world’s most pressing crises—from food shortages to pandemic disease to climate change—and is paving the way for inventions once relegated to science fiction.Meanwhile, these advances are shedding new light on the biggest mystery of all—how did life begin? We know that every creature on Earth came from a single cell, sparked into existence four billion years ago. And as we come closer and closer to understanding the ancient root that connects all living things, we may finally be able to achieve a second genesis—the creation of new life where none existed before.Creation takes us on a journey four billion years in the making—from the very first cell to the ground-breaking biological inventions that will shape the future of our planet.

Elegant, suggestive, and clarifying, Lewis Thomas's profoundly humane vision explores the world around us and examines the complex interdependence of all things. Extending beyond the usual limitations of biological science and into a vast and wondrous world of hidden relationships, this provocative book explores in personal, poetic essays to topics such as computers, germs, language, music, death, insects, and medicine. Lewis Thomas writes, "Once you have become permanently startled, as I am, by the realization that we are a social species, you tend to keep an eye out for the pieces of evidence that this is, by and large, good for us."

On the fiftieth anniversary of Watson and Crick receiving the Nobel Prize, a freshly annotated and illustrated edition of The Double Helix provides new insights into a scientific revolution.Published to mark the fiftieth anniversary of the Nobel Prize for Watson and Crick’s discovery of the structure of DNA, an annotated and illustrated edition of this classic book gives new insights into the personal relationships between James Watson, Frances Crick, Maurice Wilkins, and Rosalind Franklin, and the making of a scientific revolution.

One of the world’s most important scientists, Edward O. Wilson is also an abundantly talented writer who has twice won the Pulitzer Prize. In this, his most personal and timely book to date, he assesses the precarious state of our environment, examining the mass extinctions occurring in our time and the natural treasures we are about to lose forever. Yet, rather than eschewing doomsday prophesies, he spells out a specific plan to save our world while there is still time. His vision is a hopeful one, as economically sound as it is environmentally necessary. Eloquent, practical and wise, this book should be read and studied by anyone concerned with the fate of the natural world.